Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 3/20 | 0.31 |
| ▸ | CTSB | P07858 | 2/20 | 0.31 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | AKR1A1 | P14550 | 1/20 | 0.30 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL892231 | 1.00 | BACE1 (0.31) | BACE1CTSBAKR1B10MAPTAKR1A1 | |
| SCHEMBL891714 | 0.83 | BACE1 (0.35) | BACE1CTSBAKR1A1AKR1B1 | |
| SCHEMBL892228 | 0.83 | BACE1 (0.35) | BACE1CTSBAKR1A1AKR1B1 | |
| SCHEMBL892285 | 0.83 | BACE1 (0.35) | BACE1CTSBAKR1A1AKR1B1 | |
| SCHEMBL891705 | 0.83 | BACE1 (0.35) | BACE1CTSBAKR1A1AKR1B1 | |
| SCHEMBL891721 | 0.83 | BACE1 (0.35) | BACE1CTSBAKR1A1AKR1B1 | |
| SCHEMBL891784 | 0.82 | BACE1 (0.38) | BACE1CTSBAKR1B1 | |
| SCHEMBL892229 | 0.82 | BACE1 (0.38) | BACE1CTSBAKR1B1 | |
| SCHEMBL892004 | 0.80 | BACE1 (0.37) | BACE1CTSB | |
| SCHEMBL892371 | 0.80 | BACE1 (0.37) | BACE1CTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120083501-A1 | COMPOUNDS FOR TREATING NEURODEGENERATIVE DISEASES | ARRAY BIOPHARMA INC. | 2012-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120083501-A1 | COMPOUNDS FOR TREATING NEURODEGENERATIVE DISEASES | BACE1, PSEN1, PSEN2 | BACE1 1/4885CTSB 87/4885AKR1B10 1477/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.